# Stem Cell Seoul

> An educational reference on regenerative medicine in Korea: what stem-cell, exosome, PRP and polynucleotide treatments actually contain, what the published evidence does and does not support, and how Korean law regulates them.

- No exosome product holds United States FDA approval for any indication, and no stem-cell product is FDA approved for a cosmetic indication.
- Ryoncil (remestemcel-L-rknd) is an FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. That disease-specific approval does not cover cosmetic use or establish authorisation to provide it in Korea.
- A 2023 systematic review included 27 controlled alopecia trials with 1,117 participants: 18 androgenetic-alopecia trials with 713 participants and nine alopecia-areata trials with 404 participants. For androgenetic alopecia it favoured PRP for hair density with low-certainty evidence, and adverse-event reporting was incomplete.
- Exosome-containing preparations have small controlled studies and systematic reviews; variable formulations and combined procedures limit what they show.
- A 2025 systematic review of polynucleotides in aesthetic medicine found nine studies covering 219 patients, of low to moderate quality, with limited consensus on optimal use.
- Exosomes are vesicles released by cells, roughly 30 to 150 nanometres across. They are not cells and do not divide or engraft as living cells. Isolation methods differ between suppliers, which is why the International Society for Extracellular Vesicles publishes and revises minimum reporting standards, most recently MISEV2023.
- PRP is the patient's own blood, centrifuged so platelets concentrate in a small plasma volume. Platelets are anucleate cell fragments, and PRP contains no stem cells.
- Korea's Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products is in force from 8 October 2026 (Act No. 21525, amended 7 April 2026). Interventions within its advanced regenerative medicine pathway require institutional designation and plan review; specified minimally manipulated cell or tissue procedures are excluded from that definition, and product authorisation is a separate question.
- Documented complications of unproven cell-based interventions offered outside research frameworks include infection, immune rejection and tumour formation.

## Evidence guide pages
- [Stem Cell Seoul: evidence on regenerative medicine](https://stemcell-seoul.com/): Evidence on stem cells, exosomes, PRP and polynucleotides in Korea, including product differences, clinical studies and regulation.
- [Editorial policy, medical review and sources](https://stemcell-seoul.com/about-and-editorial-policy/): Medical review, sources and corrections for Stem Cell Seoul.
- [Stem Cell Clinical Trial Registration vs Approval](https://stemcell-seoul.com/clinical-trial-registration-vs-approval/): How to check a stem cell clinical trial claim: what an NCT registration shows and why it does not prove approval, effectiveness, Korean authorisation or availability at a particular clinic.
- [Evidence levels, and how to read them](https://stemcell-seoul.com/evidence-levels/): Why "studies show" is not one claim. The hierarchy from mechanism to meta-analysis, where each regenerative modality sits, and why a systematic review can still conclude that certainty is low.
- [Exosome Product Evidence Checklist: 5 Records to Ask For](https://stemcell-seoul.com/exosome-product-evidence-checklist/): Five records that connect an exosome product claim to its source, processing, characterization, lot and regulatory or research context.
- [Frequently asked questions about regenerative treatments](https://stemcell-seoul.com/faq/): Answers on FDA approval, stem cells versus exosomes, PRP for hair loss, safety, Korean regulation, and what to check in a treatment quote.
- [FDA Registered vs Approved: Reading Stem Cell and Exosome Records](https://stemcell-seoul.com/fda-registered-vs-approved-records/): What an “FDA-registered” or “FDA-listed” claim proves for stem cell and exosome products, which FDA record types exist, and how to check each one yourself.
- [Is stem cell or exosome treatment FDA approved?](https://stemcell-seoul.com/is-it-fda-approved/): Short answer: no exosome product holds US FDA approval for any indication, and no stem-cell product is approved for cosmetic use. What the FDA has published, and why "approved", "cleared" and "unapproved" mean different things.
- [Stem Cell Therapy in the US: The FDA Rules and the New State Laws](https://stemcell-seoul.com/is-stem-cell-therapy-legal-in-the-us/): How 21 CFR 1271 sorts cell products, what the Utah, Florida and Wyoming statutes require since 2024, and which records to ask for on each route.
- [How Korean law regulates regenerative medicine](https://stemcell-seoul.com/korea-regenerative-medicine-law/): Korea’s advanced regenerative medicine pathway requires institutional designation and plan review for covered interventions. Statutory exclusions and product approval are separate questions.
- [PRP and polynucleotides: evidence and comparisons](https://stemcell-seoul.com/prp-and-polynucleotides/): PRP for pattern hair loss has meta-analyses of randomised trials behind it, graded low certainty. PDRN has a real pharmacology literature. What each one is, what the trials found, and where the limits are.
- [Choosing a stem cell clinic in Seoul? Eight questions to ask (2026)](https://stemcell-seoul.com/questions-to-ask-a-clinic/): Choosing a stem cell clinic in Seoul? Eight questions on what is injected, which authorisation applies, the evidence and aftercare, with good and poor answers.
- [Safety, risks, and what has actually gone wrong](https://stemcell-seoul.com/safety-and-risks/): Documented harms from unproven cell-based interventions include infection, immune rejection and tumour formation. What the literature reports, what the better-studied modalities show, and the risk that travel adds.
- [Stem Cell Therapy in South Korea in 2026: The Records and the 2026–2030 Plan](https://stemcell-seoul.com/south-korea-stem-cell-therapy-2026/): Korea’s 2026 records: the treatment plan announced as No. 1, stem cell studies for knee and chronic pain scheduled to March 2028, and the 2025 advertising check.
- [Stem cells versus exosomes — the difference that matters](https://stemcell-seoul.com/stem-cells-vs-exosomes/): Exosomes are released by cells; they are not cells. What that means for mechanism, for regulation, and for how much evidence exists behind each.
- [What regenerative medicine actually covers](https://stemcell-seoul.com/what-is-regenerative-medicine/): The four families of product sold as regenerative aesthetics — living cells, platelet-rich plasma, exosomes and conditioned media, and polynucleotides — with what each one contains and what has been studied.

## Translated editions
- [Stem Cell Seoul — دليل قائم على الأدلة حول الطب التجديدي في كوريا](https://stemcell-seoul.com/ar/): مكونات الخلايا الجذعية والإكسوسومات وPRP والبولينيوكليوتيدات وأبحاثها السريرية وتنظيمها وسلامتها في كوريا.
- [Stem Cell Seoul — 韓国における再生医療のエビデンスガイド](https://stemcell-seoul.com/ja/): 韓国の幹細胞、エクソソーム、PRP、ポリヌクレオチドの成分、臨床研究、規制、安全性。
- [Stem Cell Seoul — 한국의 재생의료, 근거 중심 안내](https://stemcell-seoul.com/ko/): 한국의 줄기세포·엑소좀·PRP·폴리뉴클레오타이드의 차이, 임상 연구와 규제에 관한 정보입니다.
- [Stem Cell Seoul — คู่มืออิงหลักฐานเกี่ยวกับเวชศาสตร์ฟื้นฟูสภาวะเสื่อมในเกาหลี](https://stemcell-seoul.com/th/): สเต็มเซลล์ เอ็กโซโซม PRP และพอลินิวคลีโอไทด์ในเกาหลี: ส่วนประกอบ หลักฐานทางคลินิก ความเสี่ยง และกฎหมายที่เกี่ยวข้อง
- [Stem Cell Seoul — hướng dẫn dựa trên bằng chứng về y học tái tạo tại Hàn Quốc](https://stemcell-seoul.com/vi/): Tế bào gốc, exosome, PRP và polynucleotide tại Hàn Quốc: thành phần, bằng chứng lâm sàng, rủi ro và quy định.
- [Stem Cell Seoul — 韩国再生医学循证指南](https://stemcell-seoul.com/zh-cn/): 韩国干细胞、外泌体、PRP和多核苷酸的成分、临床研究、监管与安全性。

## Cited reviews and trials
- [Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges](https://pubmed.ncbi.nlm.nih.gov/39761139/): Haykal D, Wyles S, Garibyan L, Cartier H, Gold M. J Drugs Dermatol. 2025;24(1):12-18. doi:10.36849/JDD.8872
- [Platelet-rich plasma for the treatment of alopecia: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34967722/): Cruciani M, Masiello F, Pati I, Marano G, Pupella S, De Angelis V. Blood Transfus. 2023;21(1):24-36. doi:10.2450/2021.0216-21
- [Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study](https://pubmed.ncbi.nlm.nih.gov/37377400/): Park GH, Kwon HH, Seok J, et al. J Cosmet Dermatol. 2023;22(12):3418-3426. doi:10.1111/jocd.15872
- [Effectiveness of regenerative medicine for skin lightening and rejuvenation: a systematic review of extracellular vesicles and conditioned media](https://pubmed.ncbi.nlm.nih.gov/41013717/): Jafarzadeh A, Hoseini SS, Behrangi E, Roohaninasab M, Goodarzi A. Stem Cell Res Ther. 2025;16(1):513. doi:10.1186/s13287-025-04592-z
- [The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/39645667/): Lampridou S, Bassett S, Cavallini M, Christopoulos G. J Cosmet Dermatol. 2025;24(2):e16721. doi:10.1111/jocd.16721
- [Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches](https://pubmed.ncbi.nlm.nih.gov/38326288/): Welsh JA, Goberdhan DCI, O'Driscoll L, et al. J Extracell Vesicles. 2024;13(2):e12404. doi:10.1002/jev2.12404
- [International stem cell tourism: a critical literature review and evidence-based recommendations](https://pubmed.ncbi.nlm.nih.gov/34415026/): Lyons S, Salgaonkar S, Flaherty GT. Int Health. 2022;14(2):132-141. doi:10.1093/inthealth/ihab050

## Cited regulatory records
- [FDA: RYONCIL (remestemcel-L-rknd) product page](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/ryoncil)
- [첨단재생의료 및 첨단바이오의약품 안전 및 지원에 관한 법률 (Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products)](https://law.go.kr/LSW/lsInfoP.do?ancYnChk=0&chrClsCd=010202&efYd=20261008&lsiSeq=285347&urlMode=lsInfoP)

## Optional
- [llms-full.txt](https://stemcell-seoul.com/llms-full.txt)
- [sitemap.xml](https://stemcell-seoul.com/sitemap.xml)